Physician profile
N Sang
NPI 1700978046
$2,006.87
in general payments reported to CMS, 2019-2025
25 companies · $507 in 2025
The $507 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.48 · 2020: $22.97 · 2021: $355 · 2022: $371 · 2023: $134 · 2024: $591 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.65 | 2024-2025 | Ozempic |
| Abbvie INC. | $255.68 | 2019-2024 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $168.76 | 2019-2025 | Aptima |
| Pfizer INC. | $128.72 | 2021-2023 | |
| Therapeuticsmd, INC. | $110.04 | 2021-2022 | |
| Lilly USA, LLC | $102.87 | 2024-2025 | Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.10 | 2023-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $86.56 | 2023-2024 | Veozah |
| Dexcom, INC. | $69.25 | 2024 | Dexcom G6 Transmitter |
| Organon LLC | $63.20 | 2021-2025 | Nexplanon |
| Exact Sciences Corporation | $60.40 | 2023-2025 | Cologuard Collection Kit |
| Agile Therapeutics, INC. | $54.01 | 2022-2023 | Twirla |
| Becton, Dickinson and Company | $45.23 | 2022-2024 | Bd Onclarity |
| Dysis Medical, INC. | $45.03 | 2021-2022 | |
| Exeltis, USA INC. | $33.87 | 2025 | Slynd |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $33.75 | 2022 | |
| Myovant Sciences INC. | $26.41 | 2022 | |
| Ascend Therapeutics US, LLC | $23.36 | 2022 | |
| Acella Pharmaceuticals, LLC | $22.55 | 2024 | NP Thyroid 60 |
| Lupin INC. | $22.40 | 2021 | |
| Sumitomo Pharma America, INC. | $21.47 | 2025 | Myfembree |
| Renovia INC | $21.27 | 2021 | |
| Medtronic, INC. | $20.49 | 2022 | |
| Scynexis, INC. | $18.17 | 2022 | |
| Merck Sharp & Dohme LLC | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw N Sang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.